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Clinical
Outcome
XIENCE PRIME Observed Rate
CSR (N401)
XIENCE PRIME Observed Rate
LLR (N104)
One Year Two Years One Year Two Years
TLF (per WHO) 4.5% (18/399) 6.4% (25/392) 7.7% (8/104) 9.6% (10/104)
TLF (per ARC) 6.5% (26/399) 8.4% (33/392) 12.5% (13/104) 14.4% (15/104)
Cardiac Death 0.3% (1/399) 0.5% (2/392) 0.0% (0/104) 0.0% (0/104)
All MI (per
WHO)
1.8% (7/399) 2.0% (8/392) 4.8% (5/104) 5.8% (6/104)
All MI (per
ARC)
4.5% (18/399) 5.9% (23/392) 10.6% (11/104) 11.5% (12/104)
TV-MI (per
WHO)
1.8% (7/399) 1.8% (7/392) 4.8% (5/104) 4.8% (5/104)
TV-MI (per
ARC)
4.0% (16/399) 4.6% (18/392) 10.6% (11/104) 10.6% (11/104)






0.5% (2/399) 0.5% (2/386) 0.0% (0/104) 0.0% (0/100)
Notes: -
N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at
least one XIENCE PRIME stent and had cardiac enzyme data between 8 hours post
index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI or clinically indicated TLR.
- Time frame includes follow-up window (1-year: 365  28 days, 2-year: 730  28
days).
- TLF from hierarchical counts; other outcomes from non-hierarchical counts.
- WHO: World Health Organization.
- ARC: Academic Research Consortium.
Conclusions: The SPIRIT PRIME study demonstrated sustained 2-year safety and
efficacy of the new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates
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Background: This study was sought to investigate the impact of complete revascular-
ization (CR) vs. incomplete revascularization (IR) on long-term outcomes in patients with
multivessel coronary disease (MVD) in current practice of percutaneous coronary
intervention (PCI).
Methods: Between April 2004 and November 2010, 7376 consecutive patients with
MVD underwent PCI at our center. Patients who underwent prior CABG and those who
had an acute myocardial infarction (MI) within 24 hours before revascularization or
presented with cardiogenic shock were excluded.
Results: Among 7065 patients with MVD undergoing PCI treatment, angiographic CR
was performed in 1188 patients (16.8%), and proximal CR in 2053 patients (29.1%). The
study found that either angiographic or proximal IR were associated with significantly
higher estimated 3-year rate of cardiac death (2.55% vs. 1.13%, log-rank p0.016; and
2.70% vs. 1.43%, log-rank p0.024; respectively). After adjustment for differences in
baseline characteristics between IR and CR patients, angiographic IR was associated with
a significantly higher rate of cardiac death (adjusted hazards ratio [HR]: 2.56, 95%
confidence interval [CI]: 1.03 to 6.41) while proximal IR was associated with a
numerically higher rate of cardiac death (adjusted HR: 1.72, 95% CI: 0.93 to 3.17). For
the subgroup of 2-vessel IR with total occlusion, either angiographic or proximal IR
patients had significantly higher rate of cardiac death (adjusted HR: 4.25, 95% CI: 1.50 to
12.09; and adjusted HR: 3.02, 95% CI: 1.40 to 6.52; respectively).
Conclusions: Compared with IR, patients with CR had better clinical outcomes,
especially when only single vessels were treated, supporting CR as first choice for patients
with MVD.
TCT-611
Effect of stent inflation pressure and post-dilatation on the outcome of
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Background: PCI stent inflation pressure correlates to angiographic lumen improvement
and stent expansion but the relation to outcome is not clarified. Using comprehensive
registry data our aim was to evaluate how stent inflation pressure influences restenosis and
stent thrombosis following PCI.
Methods: We evaluated all consecutive coronary stent implantations in Sweden from
January 1, 2008, to October 26, 2011 using data from the Swedish Coronary Angiography
and Angioplasty Registry (SCAAR). We used logistic regression and Cox proportional
hazard modeling to estimate risk of outcomes with different balloon pressures.
Results: In total, 93 697 stents were eligible for analysis and divided into five different
pressure interval groups: 15 atm, 16-17 atm, 18-19 atm, 20-21 atm and 22 atm. The
risks of stent thrombosis (Fig.) and restenosis were significantly higher in the 15 atm,
18-19 atm and 22 atm groups (but not in the 16-17 atm group) compared to the 20-21
atm group. Post-dilatation was associated with a higher restenosis risk ratio (RR) of 1.22
(95% confidence interval (CI) 1.14-1.32, P0.001) but stent thrombosis did not differ
statistically between procedures with or without post-dilatation.
Conclusions: Our retrospective study identified a possible optimal stent inflation pressure
of 20-21 atm during PCI which was associated with a lower risk of stent thrombosis and
restenosis. Post-dilatation might increase restenosis risk.
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Background: Long coronary lesions are a risk factor for increased restenosis and event
rates following coronary stenting. The PLATINUM Long Lesion study evaluates the
PROMUS Element platinum chromium everolimus-eluting stent (Boston Scientific,
Natick, MA) for the treatment of long coronary lesions. Two year results have not yet
been reported.
Methods: The prospective, single-arm PLATINUM Long Lesion (LL) study enrolled
102 patients at 30 clinical sites. Patients had angina pectoris or documented silent
ischemia. One de novo target lesion24 to34mm long with reference diameter2.50
to 4.25mm could be treated with a 32 or 38mm stent. A lesion in a different epicardial
vessel could be treated with a non-study treatment before the target lesion. Exclusion
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criteria included acute or recent myocardial infarction (MI), left ventricular ejection
fraction 30%, left main or ostial location, major bifurcation disease, chronic total
occlusion, and target vessel thrombus. Routine angiographic follow-up was not per-
formed. Planned clinical follow-up is at 1, 6, 12, and 18 months, and annually to 5 years.
Results: Patients were predominantly male (62.7%), and 30.0% presented with medically
treated diabetes. At baseline, target lesion length was 24.388.21mm and reference vessel
diameter was 2.560.40mm. The study met its primary endpoint of 12-month target
lesion failure (composite of target vessel related cardiac death/MI and ischemia-driven
target lesion revascularization) with a rate of 3.2%, which was not significantly different
(p0.001) than a prespecified performance goal of 19.4% (based on historical outcomes
with 32mm paclitaxel-eluting stents, the only long drug-eluting stent approved in the US
when PLATINUM LL was initiated). At 1-year follow-up, there were 3 instances of target
lesion revascularization (3.1%), 1 non-cardiac death, and no cardiac deaths, MIs, or stent
thromboses. Two-year clinical follow-up will be reported.
Conclusions: The 1-year results of the PLATINUM LL study support the use of the
PROMUS Element 32mm and 38mm stents in the treatment of long coronary lesions.
Two-year results will be available for presentation for the first time at TCT in October
2012.
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Background: A drug-eluting stent consists of 3 components of equal importance: a
metallic platform, a polymer and a drug, all influencing acute and long term results both
in safety and efficacy. The Platinum plus trial was designed to compare the Promus
element stent to the Xience Prime. These stents have the same polymer poly (n butyl
methacrylate) (PBMA) and poly (vinylidene fluoride co hexafluoropropylene) (PVDF-
HFP)] and drug (Everolimus) but different platforms (platinum-chromium for the Promus
element, cobalt chromium for the Xience prime) and distinct stent designs.
Methods: Methods. The trial was designed as a non-inferiority single blind randomized
2:1 trial (Promus G1/XienceG2 that recruited 2985 consecutive, all-comer patients in 48
European centers. The primary endpoint was TVF at 1 year.
Results: Results. Population consisted of 79% of males, mean age: 65 yrs  9 yrs.
Indications were 42 % stable angina 31.2% ACS and 10.2 % silent ischemia. Risk factors
were well balanced between the 2 populations as follows: hypertension (65.8% vs. 68.1%,
hypercholesterolemia (66.08% vs. 65.5%), diabetes I (3.5% vs. 4.07%), diabetes II (24.8
% vs. 22.4%), insulin-treated diabetes (7.4% vs. 6.8%), family history (32.4% vs. 23.3%),
current smoker (20.4% vs. 19.9%). Procedural success was 98.4% in recipients of Promus
stents and 97.8 % for Xience prime. Mean number of stents implanted per patient was 1.7
0.8. In-hospital complications included death N3 and N1 (0.15 % and 0.10 %) for
Promus and Xience, respectively, MI N7 (0.36%) and N2 (0.19%), emergency
CABG N1 and N0 (0.05% and 0 %), repeat PCI (N4, N1). The observed
differences were statistically not significant.
Conclusions: Conclusion: No differences in acute results were observed between the 2
stents; the 30-day outcome will be available for the meeting.
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Background: Remote ischemic preconditioning (rIPC) attenuates MI4a in humans
undergoing elective percutaneous coronary intervention (PCI). However the long-term
impact of rIPC on clinical outcomes after PCI is unknown. We hypothesized that rIPC
attenuation of MI4a would improve clinical outcome at 6-years.
Methods: We randomized 215 patients with normal cardiac troponin-I (cTnI 
0.04ng/mL), undergoing elective PCI to either rIPC (n  110): three 5-minute blood
pressure cuff inflations to 200mmHg around the upper arm with 5-minutes of cuff
deflation between, or control (n  105): a deflated cuff throughout, before PCI. Patients
taking nicorandil or glibenclamide were excluded and randomization was stratified for
diabetes mellitus (DM). Post-PCI serum cardiac troponin-I (cTnI) levels were recorded at
24-hours and major adverse cardiac and cerebral event (MACCE) rate determined at
6-years (90% follow-up, mean time to event or last follow-up: 1579.7 	/ 603.6 days).
Results: The two groups were matched demographically. Median 24-hour cTnI was
significantly lower in the rIPC group (0.06 vs. 0.16ng/mL, p0.04). Mean cTnI was
higher in those with MACCE (0.91 vs. 2.07ng/mL, p0.05). MACCE rate at 6-years was
significantly lower in the rIPC group (23 vs. 36, p0.039, Figure). The non-DM subgroup
(n166) MACCE rate at 6-years was significantly lower following rIPC (17 vs. 29,
p0.045) but those with DM (n49) did not derive benefit from rIPC (6 vs. 7, p0.541).
Conclusions: Fewer patients receiving rIPC have post-PCI cTnI release and rIPC has a
superior MACCE-free survival compared to control out to 6-years.
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Background: Although the use of drug-eluting stents (DES) appears to markedly reduce
restenosis in patients undergoing percutaneous coronary interventions (PCI), there are
ongoing discussions with regards to late and very late stent thrombosis (LST and VLST).
Some reports have indicated that coarse irregularities of DES coating could play a role in
promoting stent thrombosis. The aim of this study was to investigate whether and where
damage to surface of DES occurs when the DES was delivered through a newly deployed
stent.
Methods: Fifteen coronary artery phantom models were constructed with a tube of
approximately 3 mm inner diameter. Fifteen Paclitaxel-eluting stents (PES) were
implanted in each curved tube (r20 mm). Then, the other 15 PES were delivered to pass
through the implanted stents with guide wire, and moved back and forth completely
through them three times. The entire accessible surface area of these unexpanded and
expanded stents was examined with a scanning electron microscope. Each PES was
divided into 4 equivalent parts for qualitative assessment with/without damage of
polymer. We named the most distal part as part 1 (P1) and the most proximal part as part
4 (P4), respectively.
Results: Damage was observed more frequently in distal part than in proximal part of
both expanded and unexpanded stents (as shown in figures).
Conclusions: Placement of DES through an expanded stent could cause damage to
polymer of DES. In such cases, the distal site of DES might be easy to fail to prevent
restenosis and easy to occur LST and VLST.
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